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Nuclear medicine bone imaging has been the optimum diagnosis for the detection of bone disorders because the lesion could be
detectable before the appearance of symptomatic and radiographic changes. Over the past three decades, 99mTc-MDP and 99mTc-
HMDP have been used as bone scintigraphic agents because of their superior biodistribution characteristics, although they are
far from optimal from a chemical and pharmaceutical point of view. Recently, a more logical drug design has been proposed as a
concept of bifunctional radiopharmaceuticals in which the carrier molecules (bisphosphonates) and radiometal chelating groups
are separated within a molecule, speciﬁcally, 99mTc-mononuclear complex-conjugated bisphosphonate. Some of the 99mTc-mono-
nuclear complex-conjugated bisphosphonate compounds showed superior biodistribution in preclinical studies. Moreover, the
drug design concept could be applied to 68Ga PET bone imaging agents. These studies would provide useful information for the
development of radiometal-based imaging and therapeutic agents for bone disorders such as bone metastases.
1.Background
Theskeletonisoneofthemostcommonorganstobeaﬀected
by metastatic cancer. Carcinomas of the breast, lung, pro-
state, kidney, and thyroid have a tendency to easily metas-
tasize to bone [1]. Although there has been signiﬁcant ad-
vancement in imaging technologies, such as CT and MR,
nuclear medicine bone imaging has been the optimum diag-
nosisforthedetectionofbonedisorders,suchasbonemetas-
tases, because of its high sensitivity. Namely, bone-seeking
radiopharmaceuticals usually localize in skeletal lesions
before the appearance of symptomatic and radiographic
changes and the resulting easy evaluation of the entire skel-
eton [2]. This paper reviews currently available 99mTc radio-
pharmaceuticals for bone scintigraphy and advances in drug
design of radiometal-based bone-targeted compounds.
2. 99mTc-Bisphosphonate Complexes
Although some radiometals, such as lanthanide and
rare earth, localize in bone by themselves, pertechnetate
(99mTcO4
−) hardly accumulates in bone by itself. Accord-
ingly, a carrier for bone is necessary in order to take bone
images with technetium. The ﬁrst bone-seeking 99mTc com-
pound, a complex of reduced 99mTc and sodium tripoly-
phosphate, was reported in 1971 [3], followed by a long-
chainlinearpolyphosphate[4]andpyrophosphate[5].Pyro-
phosphate (Figure 1(a))i sc o m p o s e do fo n l yt w op h o s p h a t e
moieties and is the simplest polyphosphate. 99mTc-pyro-
phosphateisnowseldomusedforskeletalimagingbecauseof
itshighsofttissuebackgroundactivitybutisstillemployedto
determine myocardial infarction. Unfortunately, pyrophos-
phate and polyphosphate are susceptible to in vivo degrada-
tion by enzymes such as alkaline phosphatases, resulting in
the release of free technetium from the complexes. Subse-
quently, three groups almost simultaneously reported the
99mTc complex of 1-hydroxyethyliden-1,1-diphosphonate
(HEDP, Figure 1(b)) as a new bone imaging agent [6–8].
HEDP is one of the bisphosphonate (diphosphonate) com-
pounds, which are known as compounds with high aﬃnity
for bone and inhibitors of bone resorption. Bisphospho-
nate compounds were synthesized with a P–C–P bonding2 International Journal of Molecular Imaging
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Figure 1: Chemical structures of bisphosphonates analogs (a)
pyrophosphate, (b) HEDP, (c) MDP, and (d) HMDP.
sequence instead of the P–O–P sequence of pyrophosphate.
Although these two chemical structures are similar, the P–
C–P bond angles are smaller (117 degrees) than the P–
O–P bond angles (128.7 degrees) and the P–C interatomic
distance (1.79 ˚ A) is longer than that of P–O (1.63 ˚ A) [9]. Bis-
phosphonate bonding is very stable chemically and aﬀords
greater resistance to in vivo phosphatase hydrolysis. As a
result, 99mTc-HEDP exhibited more rapid clearance from
blood and higher uptake in bone. In clinical study, 99mTc-
HEDP showed signiﬁcantly higher lesion-to-normal bone
ratios when compared with either 99mTc-pyrophosphate or
99mTc-polyphosphate [10].
After introduction of 99mTc-methylene diphosphonate
(MDP, Figure 1(c)) by Subramanian et al. [11] in 1975
and 99mTc-hydroxymethylene diphosphonate (HMDP,
Figure 1(d)) by Bevan et al. [12] in 1980, 99mTc-MDP, and
99mTc-HMDP, which showed superior biodistribution com-
pared to 99mTc-HEDP, have been used as radiopharmaceu-
ticals for bone scintigraphy for over thirty years [13–
15]. 99mTc-MDP is postulated to form a bidentate-bidentate
bridgewithhydroxyapatitewhilethepresenceofthehydroxyl
group in 99mTc-HMDP would convert the ligand to form a
bidentate-tridentate bridge and is expected to enhance the
hydroxyapatite aﬃnity of the 99mTc complex [12, 16]. How-
ever, the lower bone accumulation of 99mTc-HEDP is not
well understood because 99mTc-HEDP should also form
bidentate-tridentate binding. Increasing steric hindrance as-
sociated with the methyl group at the central carbon atom of
HEDP, the diﬀerence in solubility, and diﬀerences in mole-
cular size as well as in the bisphosphonate polymeric com-
plexes themselves have all been suggested [12, 17].
The accumulation of 99mTc-bisphoshonate complexes in
bone must be derived from the coordination of bisphospho-
natetocalciuminthehydroxyapatiteofbone,butthemecha-
nism of high uptake to lesion sites in bone has not been com-
pletely elucidated. One factor should be the increased vas-
cularity and regional distribution of blood ﬂow that results
from disease. However, it has been shown that regional bone
blood ﬂow alone does not account for the increased uptake
of radiopharmaceuticals [18]. Other factors are involved
in their binding and interaction with bone. It is generally
assumed that 99mTc-bisphoshonate complexes accumulate at
sites of active bone metabolism, that is to say, at areas of
new bone formation or calciﬁcation [19, 20]. It has also been
reported that the accumulation mechanisms might be both
adsorption onto the surface of hydroxyapatite in bone and
incorporationintothecrystallinestructureofhydroxyapatite
[21]. Newly formed bone has a much larger surface area
than does stable bone. That is, the crystalline structure of
hydroxyapatite in newly formed bone is amorphous and has
a greater surface area than that in normal bone [22]. An in
vitro study demonstrated that bisphosphonate compounds
have signiﬁcantly higher adsorption on amorphous calcium
phosphate than on crystalline calcium phosphate [17].
Bisphosphonate compounds form multiple complexes
with reduced 99mTc. By using high-performance liquid chro-
matography (HPLC), the relative composition of 99mTc-bi-
sphosphonate complexes in a reaction mixture has been
foundtovarywithpHandwithtechnetium,andwithoxygen
concentrations [23]. It has been postulated that 99mTc-bi-
sphosphonate complexes would be a mixture of monomers,
oxo-bridged dimers, and oligomeric clusters with varying
technetium-oxo core conﬁgurations, oxidation states, and
ligand coordination numbers [24]. These radiolabeled spe-
cies have diﬀerent biodistribution properties. It was reported
that the smallest, low-charged, mononuclear 99mTc-bisphos-
phonate complex has the greatest uptake in bone lesions
and the highest lesion-to-muscle and lesion-to-normal bone
ratios in experiments using each isolated complex by HPLC
[25]. Thus, the exact structures and mechanisms of the
action of 99mTc-labeled bisphosphonate remain uncertain.
3. New DrugDesign Concept of 99mTc-Labeled
Bisphosphonate (99mTc Complex-Conjugated
Bisphosphonate Compounds)
As mentioned above, despite over three decades of clinical
use of 99mTc-bisphosphonate complexes, these radiophar-
maceuticals are far from optimal from a chemical and
pharmaceutical point of view. For example, their structures
and compositions remain unknown because they cannot be
obtained as a well-deﬁned single-chemical species, but as
mixtures of short-chain and long-chain oligomers. The bio-
logical behavior of this type of tracer is also aﬀected by
the diﬀerent degrees of ionization and by variations in the
relative amount of oligomers after preparation [23].
In addition, in clinical studies, an interval of 2 to 6 hours
is required between an injection of 99mTc-labeled bisphos-
phonates and obtaining bone images [15]. Shortening this
interval would lessen the burden to patients in terms of total
examination length and radiation dose absorbed. To enable
imaging at an earlier time after injection, a radiopharmaceu-
tical with higher aﬃnity for bone might be advantageous.
Although the accumulation of bisphosphonate compounds
in bone is achieved by binding the phosphonate groups with
the Ca2+ of hydroxyapatite crystals [26], the phosphonate
groups in 99mTc-MDP and 99mTc-HMDP serve as both coor-
dinating ligands and Ca2+ binding functional groups [27],
which might decrease the inherent accumulation of MDP
and HMDP in bone.
Recently, to improve the 99mTc-labeled bisphosphonates
currentlyused,amorelogicaldrugdesignhasbeenproposed
based on the concept of bifunctional radiopharmaceuticals
in which the carrier molecules (bisphosphonate) and radi-
ometal chelating groups are separated within the moleculeInternational Journal of Molecular Imaging 3
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Figure 2: Chemical structures of Tc-complex-conjugated bisphosphonate compounds (a) Tc-ECAMDP, (b) Tc-MAG3-HBP, (c) Tc-
HYNIC-HBP, (d) Tc(CO)3(κ3-pz-BPOH)]+, and (e) Tc(CO)3-DPA-alendronate.
so that they can each function independently and eﬀectively.
In particular, 99mTc-mononuclear complex-conjugated bi-
sphosphonate compounds have been reported [28–31]. It
was hypothesized that the bone aﬃnity of 99mTc labeled bi-
sphosphonate would be enhanced by conjugating a stable
mononuclear 99mTc chelating group with a bisphosphonate
moiety so that the conjugation does not impair the inherent
chemical and biological properties of the bisphosphonate
compounds. 99mTc-L,L-ethylenedicysteine(EC), 99mTc-mer-
captoacetylglycylglycylglycine (MAG3), 99mTc-6-hydrazino-
nicotinic acid (HYNIC), 99mTc-tricarbonyl anchored by py-
razolyl- (pz-) containing ligand, and 99mTc-tricarbonyl di-
picolylamine (DPA) were selected as 99mTc chelating mole-
cules,andwereconjugatedwithbisphosphonatecompounds,
(99mTc-ECAMDP, 99mTc-MAG3-HBP, 99mTc-HYNIC-HBP,
[99mTc(CO)3(κ3-pz-BPOH)]+,a n d99mTc(CO)3-DPA-alen-
dronate, resp., Figure 2).
In the drug design of the 99mTc-mononuclear complex-
conjugated bisphosphonate compounds, since these ligands
contain a bisphosphonate site, there is a possibility that
99mTc coordinates not with the proposed metal coordination
moiety, such as EC, MAG3, and HYNIC but with the bis-
phosphonate moiety. To ascertain whether 99mTc is chelated
with only the proposed metal coordination moiety, some
experiments were performed. For example, in the case of
99mTc-HYNIC-HBP, 99mTc-HYNIC-HBP was also prepared
by the coupling of 99mTc-HYNIC previously complexed with
the bisphosphonate site (prelabel method). RP-HPLC ana-
lysisrevealedthe 99mTc-HYNIC-HBPbytheprelabelmethod
to be identical to that obtained from the labeling of HYNIC-
HBP with 99mTc. These ﬁndings exclude the possibility of
complexation between technetium and the bisphosphonate
structure, and indicate the chelation of 99mTc with the
HYNIC moiety in HYNIC-HBP.
In these new compounds, 99mTc-MAG3-HBP, 99mTc-
HYNIC-HBP,and 99mTc(CO)3-DPA-alendronatewereinves-
tigated for in vitro hydroxyapatite binding as an index of
bone aﬃnity. 99mTc-MAG3-HBP and 99mTc-HYNIC-HBP
showed a signiﬁcantly higher rate of binding to hydroxyap-
atite than did 99mTc-HMDP. 99mTc(CO)3-DPA-alendronate
showed a higher aﬃnity to hydroxyapatite than did 99mTc-
MDP. At the same time, all new 99mTc-mononuclear4 International Journal of Molecular Imaging
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Figure 3: Chemical structures of radiogallium complex-conjugated bisphosphonate compounds (a) Ga-DOTA-Bn-SCN-HBP and (b) Ga-
BPAMD.
complex-conjugated bisphosphonate compounds exhibited
high bone uptake in in vivo animal experiments. 99mTc-EC-
AMDP and 99mTc-HYNIC-HBP showed especially superior
results; 99mTc-EC-AMDP and 99mTc-HYNIC-HBP showed
signiﬁcantly higher bone-to-blood ratios of radioactivity
than did 99mTc-MDP and 99mTc-HMDP.
4.Radiogallium-LabeledCompounds as
Bone Imaging Agents for PET
68Ga is one of the greatest practical and interesting radionu-
clides for clinical positron emission tomography (PET) be-
cause of its radiophysical properties (T1/2 = 68min) [32].
68Gaisagenerator-producednuclideandcanbeelutedatany
time on demand. Speciﬁcally, it does not require an on-site
cyclotron.Inprinciple,thelonghalf-lifeoftheparentnuclide
68Ge (T1/2 = 270.8 days) provides a long life-span generator.
Investigations of 68Ga-labeled compounds for bone im-
aging were previously reported in the 1970s [33, 34]. In these
reports, gallium was labeled with tripolyphosphate or eth-
ylenediamine tetramethylene phosphonate (EDTMP) or di-
ethylenetriamine pentamethylene phosphonate (DTPMP).
These complexes showed high uptakes in bone. However,
since use of the PET camera generally did not spread in the
1970sandthequalityofPETcameraswasnothigh,theatten-
tion given to 68Ga PET imaging agents was not so high.
For the last decade, 68Ga as a nuclide has been considered
a useful radionuclide for PET imaging. Thus, many 68Ga-
labeled compounds have been developed. Recently, 68Ga-
EDTMP was also reevaluated by Mitterhauser et al. [35].
However, they stated that the advantage of 68Ga-EDTMP
over [18F]-ﬂuoride was not apparent and that the future clin-
ical prospect of 68Ga-EDTMP remained speculative.
The above-mentioned drug concept of stable mononu-
clear complex-conjugated bisphosphonate could be applica-
ble to not only technetium complex radiopharmaceuticals
but also to gallium radiopharmaceuticals. To develop a new
PET tracer with radiogallium for imaging bone disorders
suchasbonemetastases,1,4,7,10-tetraazacyclododecane-1,4,
7,10-tetraacetic acid (DOTA) was chosen as a chelating site
because it has been well known that Ga forms a stable
complex with DOTA. Therefore, Ga-DOTA-conjugated bis-
phosphonate compounds (67Ga-DOTA-Bn-SCN-HBP and
68Ga-BPAMD, Figure 3) have been developed [36, 37]. Actu-
ally, in biodistribution experiments, 67Ga-DOTA-Bn-SCN-
HBP rapidly accumulated in bone but was rarely observed
in tissues other than bone. In addition, PET/CT imaging of
bone metastases with 68Ga-BPAMD showed high uptake in
osteoblastic metastases of human (Figure 4). The maximal
standardized uptake was 77.1 and 62.1 in the 10th thoracic
and L2 vertebra versus 39.1 and 39.2 for 18F-ﬂuoride PET, re-
spectively. These results suggest that the drug design concept
of radiogallium complex-conjugated bisphosphonate could
be useful for the development of 68Ga PET imaging agents
for bone disorders such as bone metastases.
5. 18F-Fluoride as Bone Imaging Agent for PET
18F-ﬂuoride was initially reported by Blau et al. in 1962 [38].
After the development of 99mTc-labeled bone scintigraphy
agents, such as 99mTc-MDP, 18F-ﬂuoride was replaced by
thembecausethephysicalcharacteristicsof 99mTc were more
convenient for imaging with conventional gamma cameras
in those days. However, in the last decade, PET and PET/CT
have evolved signiﬁcantly and become widespread. The situ-
ation has similarly changed for 68Ga-labeled compounds.
The changes caused the reemergence of 18F-ﬂuoride bone
imaging with PET because current PET cameras have higher
spatial resolution and greater sensitivity than conventional
gamma cameras.
Like 99mTc-MDP as mentioned above, it is known
that the distribution of 18F-ﬂuoride in bone also reﬂects
both blood ﬂow in bone and osteoblastic activity. Once
18F-ﬂuoride reaches the surface of the newly formed
hydroxyapatite crystals, ﬂuoride anions are isomorphously
exchanged with the hydroxyl group in hydroxyapatite
(Ca10(PO4)6(OH)2) and ﬂuorapatite (Ca10(PO4)6F2)i s
formed [39]. A previous paper reported that electron probe
X-ray ﬂuorescence studies on the topographical distribution
of ﬂuoride at the microscopic level in the iliac bone of an
osteoporotic patient being treated with ﬂuoride [40]. The
results indicate that the distribution of 18F-ﬂuoride in newly
mineralized bone is similar to that of 99mTc-MDP.
There is an important diﬀerence between 18F-ﬂuoride
and 99mTc-MDP in terms of their protein binding rates. 18F-
ﬂuoride barely binds to serum protein [41]w h e r e a s99mTc-
MDP shows signiﬁcant protein bindings. The diﬀerence
in protein binding causes a diﬀerence in blood clearance
between 18F-ﬂuoride and 99mTc-MDP. Hence, an interval of
2-3 hours is needed between an injection of 99mTc-MDP and
bone imaging. In contrast, bone imaging can be performed
less than 1 hour after an injection of 18F-ﬂuoride. AnotherInternational Journal of Molecular Imaging 5
(a) (b)
(c)
Figure 4: 68Ga-BPAMD was injected i.v. into a patient with known
extensive bone metastases of prostate cancer. 68Ga-BPAMD (max-
imum intensity projection (MIP) 50min after injection (p.i.),
462MBq) revealed intense accumulation in multiple osteoblastic
lesions in the central skeleton, ribs, and proximal extremities: (a) =
coronal PET, (b) = sagittal PET/CT. For comparison, (c) shows
18F-ﬂuoride PET (sagittal, MIP 90min p.i., 270MBq). With kind
permission from Springer Science + Business Media: [36].
diﬀerence between 18F-ﬂuoride and 99mTc-MDP is in terms
of uptake to blood cells. 18F-ﬂuoride is taken up by red
blood cells. The erythrocyte concentration of 18F-ﬂuoride is
approximately 45–50% of the plasma concentration, namely,
approximately 30% of total blood concentration. However,
18F - ﬂ u o r i d ei sf r e e l yd i ﬀusible from red blood cells to the
bone surface, so the uptake of 18F-ﬂuoride to red blood cells
should not interfere with the accumulation of 18F-ﬂuoride in
bone [41].
In clinical use in oncology, some papers reported on a
comparison between 18F-ﬂuoride PET and planar 99mTc-
MDP scintigraphy in the detection of bone metastases [42,
43]. 18F-ﬂuoride PET was more sensitive in detecting bone
metastases than planar 99mTc-MDP scintigraphy. However,
the cause of increased sensitivity—whether it was derived
from 18F-ﬂuoride itselfasatracerorbecauseoftheimproved
performance of the PET camera—could not be determined.
Speciﬁcally, 18F-ﬂuoride PET has two important advan-
tages in diagnosis imaging over planar 99mTc-MDP scintig-
raphy: superior sensitivity and a shorter interval between
injection of a tracer and bone imaging. Thus, the use of 18F-
ﬂuoride could become common in the future.
6. Conclusion
Over the past three decades, 99mTc-MDP and 99mTc-HMDP
have been used for detecting bone metastases, although
their mechanisms of accumulation remain uncertain. Recent
eﬀorts of chelate-conjugated bisphosphonates and their
derivatives have provided chemically well-characterized new
99mTc-labeled bone-seeking tracers. Furthermore, the drug
design concept could be applied to 68Ga PET bone imaging
agents. These studies would provide useful information for
thedevelopmentofradiometal-basedimagingandtherapeu-
tic agents for bone disorders such as bone metastases.
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